liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy. in BLOOD, vol 114, issue 22, pp 1269-1270
Uppsala University Hospital.
University of Oslo, Rikshospital.
Umeå University Hospital.
Turku University.
Show others and affiliations
2009 (English)In: BLOOD, American Society of Hematology , 2009, Vol. 114, no 22, 1269-1270 p.Conference paper, Published paper (Refereed)
Abstract [en]

n/a

Place, publisher, year, edition, pages
American Society of Hematology , 2009. Vol. 114, no 22, 1269-1270 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-58392ISI: 000272725803835OAI: oai:DiVA.org:liu-58392DiVA: diva2:343280
Available from: 2010-08-13 Created: 2010-08-11 Last updated: 2010-08-13

Open Access in DiVA

No full text

Authority records BETA

Malm, Claes

Search in DiVA

By author/editor
Malm, Claes
By organisation
Oncology Faculty of Health SciencesDepartment of Haematology UHL
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 66 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf